Patents Assigned to MedImmune, Inc.
-
Publication number: 20050181479Abstract: The present invention relates to recombinant polynucleotides, expression vectors and methods for the production of multimeric proteins. The vectors and methods are useful for the production of multimeric protein and are unique in that they utilize a minimal number of signal sequences. More specifically, the present invention provides recombinant polynucleotide molecules and expression vectors comprising a promoter region operably linked to a transcription unit. The transcription unit is characterized by at least two DNA sequences encoding distinct polypeptides wherein at least one but not all DNA sequences further encodes a signal sequence operably linked to the DNA sequence encoding a polypeptide. The invention further provides methods of producing a multimeric protein using the expression vectors of the present invention.Type: ApplicationFiled: March 4, 2005Publication date: August 18, 2005Applicant: MEDIMMUNE, INC.Inventors: William Dall'Acqua, Herren Wu, Melissa Damschroder
-
Publication number: 20050158342Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. In addition, the present invention includes an improved method of rescue, wherein animal cells (e.g., SF Vero cells) are electroporated with plasmids and vectors of the invention.Type: ApplicationFiled: December 22, 2004Publication date: July 21, 2005Applicant: MEDIMMUNE, INC.Inventors: George Kemble, Gregory Duke
-
Patent number: 6913750Abstract: A protein construct comprising a pilus protein portion, preferably a structurally stabilized pilus-protein, and an additional, or effector, portion other than a pilus protein or chaperone and wherein said effector portion serves to stabilize the pilus protein portion and to confer a therapeutic activity, such as vaccine activity or anti-microbial or anticancer activity, on the protein construct is disclosed. Such effector portion commonly comprises a donor strand complementary segment capable of structurally stabilizing a pilus protein subunit and attaching the auxiliary portion to said subunit to form the pilus protein analog of the invention. Methods of using said protein constructs are also disclosed as well as the formation and use of analogs comprising fragments of a pilus protein linked to effector components to produce immunogenic and/or therapeutic activity.Type: GrantFiled: December 28, 2001Date of Patent: July 5, 2005Assignees: MedImmune, Inc., Washington UniversityInventors: Scott J. Hultgren, Solomon Langermann, Frederic G. Sauer
-
Patent number: 6908613Abstract: Disclosed are chimeric HPV L1 proteins and virus like particles comprising the same which are capable of generating high titer neutralizing antibody responses against at least two HPV types. The disclosed chimeric HPV L1 proteins and VLPs are useful as therapeutic and prophylactic reagents, as well as reagents for diagnosing papillomavirus infection.Type: GrantFiled: June 8, 2001Date of Patent: June 21, 2005Assignee: MedImmune, Inc.Inventors: Susan D. Wilson, Wendy White, JoAnn Suzich, Brian Mullikin
-
Patent number: 6887480Abstract: The present invention relates to novel immunogenic polypeptides, and fragments thereof, and vaccines for the prevention and treatment of pneumococcal infection, especially by Streptococcus pneumoniae. The invention also relates to antibodies against the disclosed polypeptides, as well as vaccines containing said polypeptides and methods of disease prevention.Type: GrantFiled: June 9, 2000Date of Patent: May 3, 2005Assignee: MedImmune, Inc.Inventors: John E. Adamou, Gil H. Choi
-
Patent number: 6863893Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with pneumococcal derived polypeptides that include an alpha helix but exclude a choline binding region as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnositics and/or as protective/treatment agents for pathogenic bacterial species.Type: GrantFiled: September 25, 2002Date of Patent: March 8, 2005Assignee: MedImmune, Inc.Inventors: Theresa M. Wizemann, Scott Koenig, Leslie S. Johnson
-
Publication number: 20050048550Abstract: EphA2 T-cell epitope agonists are provided herein. The agonists include peptides corresponding to specific fragments of human EphA2 protein containing one or more T-cell epitopes, and conservative derivatives thereof. The EphA2 T-cell epitope agonists are useful in an assay, such as an ELISPOT assay, that may be used to determine and/or quantify a patient's immune responsiveness to EphA2. The agonists also are useful in methods of modulating a patient's immune reactivity to EphA2, which has substantial utility as a treatment for cancers that overexpress EphA2, such as renal cell carcinoma (RCC). The EphA2 agonists also can be used to vaccinate a patient against EphA2, by in vivo or ex vivo methods.Type: ApplicationFiled: July 22, 2004Publication date: March 3, 2005Applicants: University of Pittsburgh-of the Commonwealth System of Higher Education, Medimmune, Inc.Inventors: Walter Storkus, Michael Kinch
-
Publication number: 20050048617Abstract: The present invention relates to methods of reengineering or reshaping antibodies to reduce the immunogenicity of the antibodies, while maintaining the immunospecificity of the antibodies for an antigen. In particular, the present invention provides methods of producing antibodies immunospecific for an antigen by synthesizing a combinatorial library comprising complementarity determining regions (CDRs) from a donor antibody fused in frame to framework regions from a sub-bank of framework regions. The present invention also provides antibodies produced by the methods of the invention.Type: ApplicationFiled: August 18, 2004Publication date: March 3, 2005Applicant: MEDIMMUNE, INC.Inventors: Herren Wu, William Dall-Acqua, Melissa Damschroder
-
Publication number: 20050042664Abstract: The present invention provides methods of re-engineering or re-shaping an antibody from a first species, wherein the re-engineered or re-shaped antibody does not elicit undesired immune response in a second species, and the re-engineered or re-shaped antibody retains substantially the same antigen binding-ability of the antibody from the first species. In accordance with the present invention, a combinatorial library comprising the CDRs of the antibody from the first species fused in frame with framework regions derived from a second species can be constructed and screened for the desired modified antibody. In particular, the present invention provides methods utilizing low homology acceptor antibody frameworks for efficiently humanizing an antibody or a fragment thereof. The present invention also provides antibodies produced by the methods of the invention.Type: ApplicationFiled: August 20, 2004Publication date: February 24, 2005Applicant: MEDIMMUNE, INC.Inventors: Herren Wu, William Dall-Acqua, Melissa Damschroder
-
Patent number: 6858706Abstract: This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides a isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate.Type: GrantFiled: April 7, 1998Date of Patent: February 22, 2005Assignees: St. Jude Children's Research Hospital, MedImmune, Inc.Inventors: Elaine I. Tuomanen, Theresa M. Wizemann, H. Robert Masure, Leslie Sydnor Johnson, Scott Koenig
-
Patent number: 6855493Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: November 28, 2001Date of Patent: February 15, 2005Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson, William D. Huse, Jeffrey D. Watkins
-
Patent number: 6833356Abstract: The invention is directed to isolated polypeptides bearing sequence homology to the Sp36 protein found in pneumococcal organisms, such as Streptococcus pneumoniae. Polynucleotides encoding such polypeptides are also disclosed. The invention also relates to antibodies specific for the disclosed polypeptides and to uses of such antibodies in the treatment of diseases caused by staphylococci as well as group A and B streptococci. In addition, the invention relates to the use of the disclosed polypeptides in compositions and as vaccines and for prophylactic uses such as in vaccination of animals, especially humans, against a wide variety of streptococcal, staphylococcal and other diseases.Type: GrantFiled: August 25, 2000Date of Patent: December 21, 2004Assignee: Medimmune, Inc.Inventors: Scott Koenig, Jon Heinrichs, Leslie S. Johnson, John E. Adamou
-
Patent number: 6818216Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: GrantFiled: November 28, 2001Date of Patent: November 16, 2004Assignee: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson
-
Publication number: 20040208870Abstract: The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin &agr;V&bgr;3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin &agr;V&bgr;3, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin &agr;V&bgr;3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.Type: ApplicationFiled: January 30, 2004Publication date: October 21, 2004Applicant: MedImmune, Inc.Inventor: Christian B. Allan
-
Publication number: 20040208869Abstract: The present invention provides liquid formulations of antibodies or antibody fragments that immunospecifically bind to integrin &agr;v&bgr;3, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to integrin &agr;v&bgr;3, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating an inflammatory disorder, an autoimmune disorder, a disorder associated with aberrant expression and/or activity of integrin &agr;v&bgr;3, a disorder associated with abnormal bone metabolism, a disorder associated with aberrant angiogenesis or cancer utilizing the liquid formulations of the present invention.Type: ApplicationFiled: January 30, 2004Publication date: October 21, 2004Applicant: MedImmune, Inc.Inventor: Christian B. Allan
-
Publication number: 20040176272Abstract: The present invention provides methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, utilizing antagonists of integrin &agr;v&bgr;3. The present invention encompasses the use of methods of preventing, treating, managing or ameliorating periodontal disease, Gorham-Stout disease, Wilson's disease, chronic otitis media, hypertrophic pulmonary osteoarthropathy, or aseptic loosening of joint replacement (prostheses), or conditions associated therewith, utilizing an integrin &agr;v&bgr;3 antagonist in combination with another therapy (e.g., another prophylactic or therapeutic agent).Type: ApplicationFiled: January 30, 2004Publication date: September 9, 2004Applicant: MedImmune, Inc.Inventors: Ronald L. Wilder, Su-Yau Mao
-
Publication number: 20040120966Abstract: This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate in which the amino acid sequence is set forth in any of SEQ ID NOS: 1, 3-7, or 9-11, including fragments, mutants, variants, analogs, or derivatives, thereof. Also, this invention provides a isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the amino acid is set forth in SEQ ID NO: 24, wherein the polypeptide retains its native tertiary structure and methods of preparation. This invention provides an isolated polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate, wherein the polypeptide has lectin activity and does not bind to choline. This invention provides an isolated immunogenic polypeptide comprising an amino acid sequence of a N-terminal choline binding protein A truncate.Type: ApplicationFiled: January 5, 2004Publication date: June 24, 2004Applicants: St. Jude Children's Research Hospital, Medimmune, Inc.Inventors: Elaine I. Tuomanen, Theresa M. Wizemann, H. Robert Masure, Leslie Sydnor Johnson, Scott Koenig
-
Patent number: 6737063Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. Also provided are methods for vaccination of mammalian species, especially human patients, with variants of the E. coli FimH protein, said variants being derived from different strains of E. coli, and to production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnostics and/or as protective/treatment agents for pathogenic bacterial species. A plasmid-based method of producing polypeptides, especially fused polypeptides, such as the complex of a bacterial chaperone and a bacterial adhesin, is also disclosed.Type: GrantFiled: July 6, 2001Date of Patent: May 18, 2004Assignee: MedImmune, Inc.Inventors: Solomon Langermann, Andrew Revel, Christine Auguste, Jeanne Burlein
-
Patent number: 6689369Abstract: The present invention relates to novel immunogenic polypeptides, and therapeutically active fragments thereof, and vaccines, and vaccine compositions, for the prevention and treatment of streptococcal infection, especially by Streptococcus pneumoniae. The invention also relates to antibodies against the disclosed polypeptides, as well as methods of disease prevention and/or treatment.Type: GrantFiled: April 27, 2001Date of Patent: February 10, 2004Assignee: MedImmune, Inc.Inventors: Scott Koenig, Leslie S. Johnson, John E. Adamou
-
Publication number: 20040018200Abstract: The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long periods of storage. In particular, the present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides methods of preventing, treating or ameliorating one or more symptoms associated with RSV infection utilizing the liquid formulations of the present invention.Type: ApplicationFiled: June 13, 2003Publication date: January 29, 2004Applicant: MedImmune, Inc.Inventors: Cynthia N. Oliver, Christian B. Allan, Stephen T. Chang